
BIOGRAPHICAL SKETCH

NAME	POSITION TITLE
<p>Mian, Caterina</p> <p>Born in Padua 21 Ottobre 1970</p> <p>Address: Via S.G. da Verdara N°125 35137 Padua Italy</p> <p>Phone: 00390498214266 00393482327979</p> <p>Fax: 0039049657391</p> <p>Email: caterina.mian@unipd.it</p> <p>ORCID: 0000-0003-2615-8001</p>	<p>Associate Professor of Endocrinology, University of Padua</p>

EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.)

INSTITUTION AND LOCATION	DEGREE (if applicable)	YYYY	FIELD OF STUDY
University of Padua	Degree	1996	Medicine and Surgery
University of Padua	Specialist	2002	Endocrinology and Metabolism
University of Padua	PhD	2006	Endocrine and Hematological Sciences
University of Padua	Assistant Professor	2007	Endocrinology
Univeristy of Padua	Associate Professor	2018	Endocrinology

A. Personal Statement

She is now part of the Department of Medicine-DIMED, where she played the position of the Research Commission Member from 2013 to 2015 by the Director's decree n. 55/2012 of 10/07/2012. Currently she held the member position of the Board of Director by decree n.113 / 2015 of 11/11/2015.

The research topics to which she was devoted and which she is currently following are:

- In the last years before the degree, she specialized in the field of cell culture, devoting herself to the functional characterization of anti-TSH receptor antibodies in the line FRTL-5 cells. This project was conducted in collaboration with the Institute of General Pathology, University of Udine;
- At the Institute Gustave Roussy, she was responsible for the expression study, at the gene and protein level, of certain molecules, membrane transporters and enzymes involved in the maintenance of differentiated thyroid function (thyroglobulin, thyroid peroxidase thyroid, cotransporter Na⁺/I⁻ NIS, Pendred's Syndrome Gene PDS, DUOX 1 and 2) in benign and malignant thyroid tissue and in the context of extrathyroidal tissue;
- During the PhD, she was dedicated to a project aimed to study the molecular characterization of not iodine-fixing differentiated thyroid carcinomas, taking part as a "component" of the project PRIN 2003

2003069778_007 protocol entitled "innovative therapies for the treatment of poor prognosis thyroid carcinomas";

- She deals with sporadic and familial medullary thyroid carcinoma (FMTC, MEN2A/B): 1) searching for mutations in the RET proto-oncogene, at germinal and somatic level; 2) analyzing the relationship between genotypic and phenotypic expression of the disease in family forms. As "local charge", in the course of the 2011 CPDA118051 protocol entitled "Medullary thyroid carcinoma: impact of old and new molecular markers in the stratification of patient risk at diagnosis," she was responsible for assessing whether using known (search for somatic mutations of RET and NKX / RAS) and innovative (6 miRNAs panel) molecular markers were able to identify patients with aggressive medullary thyroid carcinoma at the diagnosis, in order to plan surgical approaches and customized follow-up;
- In June 2015 she received a grant from the IBSA company as a Principal Investigator for a research grant for a project entitled: "synthetic and natural compounds in medullary thyroid carcinoma, innovative anti-tumor effects in preclinical studies";
- From February 2016 to January 2018 she will be the scientific coordinator of a Senior Research Grant entitled "From bench to bedside: new approach for the treatment of medullary thyroid carcinoma" won by Dr. Loris Bertazza;
- She has coordinated several epidemiological studies evaluating the impact of goiter and iodine deficiency in the Region of Veneto in the of school age population and during pregnancy;
- Since 2012 she is Head of the Regional Reference Framework for Iodine prophylaxis of Veneto (structure created with D.R.G.N ° 1935 22 November 2011). This structure is designed to promote and coordinate in the Veneto Region, the following initiatives: 1) effectiveness and efficiency monitoring of iodine prophylaxis program; 2) promotion of the use of iodized salt awareness campaign 3) start of corrective actions to improve the iodine availability in the Veneto Region;
- She has done **Referee activities** for the following international peer-reviewed journals:
 - Thyroid
 - Journal of Clinical Endocrinology and Metabolism
 - Endocrine Research
 - Endocrine
 - Endocrine-related Cancer
 - British Journal of Nutrition
 - Frontiers Endocrinology
 - Clinical Endocrinology
 - Clinical Chemistry and Laboratory Medicine
 - Expert review of Endocrinology and Metabolism
 - Archives of Medical Sciences
 - Journal of Endocrinological Investigation
 - World Journal of Surgical Oncology
 - Saudi medical Journal
 - Medical Science Monitor
- **Member of the Editorial Board**
 - Frontiers Endocrinology
 - Current Gene therapy
 - Journal of Endocrine society

B. Positions and Honors

Professional experience and teaching activity

- From 1999 to 2001 she works at Oncological Institute Gustave Roussy in Villejuif-Paris with Professor Martin Schlumberger.

- Since 2007 she is head of the Molecular Biology Laboratory of the Endocrinology Unit at Hospital of Padua, where the following genetic tests are performed: RET, Menin, AIP, BRAF, RAS, AIRE, TSHR and PRKAR1A analysis;
- Since 2012 she is Head of the laboratory of Thyroid Pathophysiology, where the dosage of iodine concentration in the urine is carried out;
- Since 2012 she is Head of the Regional Reference Framework for Iodine prophylaxis of the Veneto Region (Legislative Decree No. 1935, dated 22/11/2011)
- At the Endocrinology Unit of Padua hospital, she is responsible for 1) thyroid oncology ambulatories, where patients with differentiated thyroid cancer and MTC (sporadic and familial) are taken in charge; 2) pregnancy endocrine disorders ambulatories; and 3) the ambulatory of Graves' orbitopathy;
- She teaches at several degree courses at the University of Padua;
- She is part of the teaching staff of the PhD program in Clinical and Experimental Sciences at the University of Padua, from 2012;
- Professor at the Master School of "Endocrinology and Metabolic Diseases" from the year 2007;
- Associate Professor of Endocrinology at the University of Padua from the year 2018.

Scientific Societies and Role

- Member of the Italian Society of Endocrinology (SIE), which is among the members of the Scientific Commission;
- Elected among the delegates of the Regional Council of the Italian Society of Endocrinology, section Triveneto from 02/29/2016;
- Member of the Italian Society of the Thyroid (AIT), which is among the members of the Board;
- Member of the European Thyroid Association (ETA);
- Member of the American Thyroid Association (ATA).

Speaker, Moderator or Discussant in more than 50 national and international congresses.

Publications

More than 90 Publications

HI 28

Total citations: 2348

C. Peer-reviewed Publications

1. Shen, X., Zhu, G., Liu, R., Viola, D., Elisei, R., Puxeddu, E., Fugazzola, L., Colombo, C., Jarzab, B., Czarniecka, A., Lam, A.K., Mian, C., Vianello, F., Yip, L., Riesco-Eizaguirre, G., Santisteban, P., O'Neill, C.J., Sywak, M.S., Clifton-Bligh, R., Bendlova, B., Sykorova, V., Xing, M. Patient age-associated mortality risk is differentiated by BRAF V600E status in papillary thyroid cancer (2018) *Journal of Clinical Oncology*, 36 (5), pp. 438-445.
2. Torresan, F., Cavedon, E., Mian, C., Iacobone, M. Long-Term Outcome After Surgery for Medullary Thyroid Carcinoma: A Single-Center Experience (2018) *World Journal of Surgery*, 42 (2), pp. 367-375.

3. Rubin, B., Mansi, J., Monticelli, H., Bertazza, L., Redaelli, M., Sensi, F., Zorzan, M., Scaroni, C., Mian, C., Iacobone, M., Armanini, D., Bertolini, C., Barollo, S., Boscaro, M., Pezzani, R. Crude extract of *Origanum vulgare* L. induced cell death and suppressed MAPK and PI3/Akt signaling pathways in SW13 and H295R cell lines (2018) *Natural Product Research*, pp. 1-4. Article in Press.
4. Olivieri A, DI Cosmo C, DE Angelis S, DA Cas R, Stacchini P, Pastorelli A, Vitti P; Regional Observatories for Goiter Prevention. The way forward in Italy for iodine. *Minerva Med.* 2017 Apr;108(2):159-168. doi: 10.23736/S0026-4806.17.04877-7. Epub 2017 Jan 12. Review.
5. Lamartina, L., Durante, C., Lucisano, G., Grani, G., Bellantone, R., Lombardi, C.P., Pontecorvi, A., Arvat, E., Felicetti, F., Zatelli, M.C., Rossi, R., Puxeddu, E., Morelli, S., Torlontano, M., Crocetti, U., Montesano, T., Giubbini, R., Orlandi, F., Aimaretti, G., Monzani, F., Attard, M., Francese, C., Antonelli, A., Limone, P., Rossetto, R., Fugazzola, L., Meringolo, D., Bruno, R., Tumino, S., Ceresini, G., Centanni, M., Monti, S., Salvatore, D., Spiazzi, G., Mian, C., Persani, L., Barbaro, D., Nicolucci, A., Filetti, S. Are Evidence-Based Guidelines Reflected in Clinical Practice? An Analysis of Prospectively Collected Data of the Italian Thyroid Cancer Observatory (2017) *Thyroid*, 27 (12), pp. 1490-1497.
6. Huang Y, Qu S, Zhu G, Wang F, Liu R, Shen X, Viola D, Elisei R, Puxeddu E, Fugazzola L, Colombo C, Jarzab B, Czarniecka A, Lam AK, Mian C, Vianello F, Yip L, Riesco-Eizaguirre G, Santisteban P, O'Neill CJ, Xing M, Sywak MS, Clifton-Bligh R, Bendlova B, Sýkorová V. BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment. *J Natl Cancer Inst.* 2017 Nov 18. doi: 10.1093/jnci/djx227. [Epub ahead of print] PubMed PMID: 29165667.
7. Galuppini, F., Bertazza, L., Barollo, S., Cavedon, E., Rugge, M., Guzzardo, V., Sacchi, D., Watutantrige-Fernando, S., Vianello, F., Mian, C., Pennelli, G. MiR-375 and YAP1 expression profiling in medullary thyroid carcinoma and their correlation with clinical-pathological features and outcome (2017) *Virchows Archiv*, 471 (5), pp. 651-658.
8. Censi, S., Cavedon, E., Bertazza, L., Galuppini, F., Watutantrige-Fernando, S., De Lazzari, P., Nacamulli, D., Pennelli, G., Fassina, A., Iacobone, M., Casal Ide, E., Vianello, F., Barollo, S., Mian, C. Frequency and significance of Ras, Tert promoter, and Braf mutations in cytologically indeterminate thyroid nodules: A monocentric case series at a tertiary-level Endocrinology unit (2017) *Front Endocrinol (Lausanne)*. Oct 16;8:273.
9. Wang, F., Yu, X., Shen, X., Zhu, G., Huang, Y., Liu, R., Viola, D., Elisei, R., Puxeddu, E., Fugazzola, L., Colombo, C., Jarzab, B., Czarniecka, A., Lam, A.K., Mian, C., Vianello, F., Yip, L., Riesco-Eizaguirre, G., Santisteban, P., O'Neill, C.J., Sywak, M.S., Clifton-Bligh, R., Bendlova, B., Sýkorová, V., Wang, Y., Liu, S., Zhao, J., Zhao, S., Xing, M. The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer (2017) *The Journal of clinical endocrinology and metabolism*, 102 (9), pp. 3241-3250.
10. Castinetti, F., Maia, A.L., Peczkowska, M., Barontini, M., Hasse-Lazar, K., Links, T.P., Toledo, R.A., Dvorakova, S., Mian, C., Joao Bugalho, M., Zovato, S., Alevizaki, M., Kvachenyuk, A., Bausch, B., Loli, P., Bergmann, S.R., Patocs, A., Pfeifer, M., Costa, J.B., Von Dobschuetz, E., Letizia, C., Valk, G., Barczynski, M., Czetwertynska, M., Plukker, J.T.M., Sartorato, P., Zelinka,

- T., Vlcek, P., Yaremchuk, S., Weryha, G., Canu, L., Wohllk, N., Sebag, F., Walz, M.K., Eng, C., Neumann, H.P.H. The penetrance of MEN2 pheochromocytoma is not only determined by RET mutations (2017) *Endocrine-Related Cancer*, 24 (8), pp. L63-L67.
11. Campi, I., Cammarata, G., Marzoli, S.B., Beck-Peccoz, P., Santarsiero, D., Dazzi, D., De Castello, A.B., Taroni, E.G., Viola, F., Mian, C., Watutantrige-Fernando, S., Pelusi, C., Muzza, M., Maffini, M.A., Persani, L. Retinal photoreceptor functions are compromised in patients with resistance to thyroid hormone syndrome (RTHb) (2017) *Journal of Clinical Endocrinology and Metabolism*, 102 (7), pp. 2620-2627.
 12. Watutantrige-Fernando, S., Vianello, F., Barollo, S., Bertazza, L., Galuppini, F., Cavedon, E., Censi, S., Benna, C., Casal Ide, E., Parisi, A., Nacamulli, D., Iacobone, M., Pennelli, G., Mian, C. The Hobnail variant of Papillary Thyroid Carcinoma: Clinical/molecular characteristics of a large monocentric series and comparison with conventional histotypes. (2018) *Thyroid*, Jan;28(1):96-103.
 13. Tuccilli, C., Baldini, E., Arlot-Bonnemains, Y., Chesnel, F., Sorrenti, S., De Vito, C., D'Armiento, E., Antonelli, A., Fallahi, P., Watutantrige, S., Tartaglia, F., Barollo, S., Mian, C., Arcieri, S., Mascagni, D., Pironi, D., Bononi, M., Vergine, M., Monti, M., Filippini, A., Ulisse, S. Expression and prognostic value of the cell polarity PAR complex members in thyroid cancer (2017) *International Journal of Oncology*, 50 (4), pp. 1413-1422.
 14. Baldini, E., Tuccilli, C., Arlot-Bonnemains, Y., Chesnel, F., Sorrenti, S., De Vito, C., Catania, A., D'Armiento, E., Antonelli, A., Fallahi, P., Watutantrige-Fernando, S., Tartaglia, F., Barollo, S., Mian, C., Bononi, M., Arceri, S., Mascagni, D., Vergine, M., Pironi, D., Monti, M., Filippini, A., Ulisse, S. Deregulated expression of VHL mRNA variants in papillary thyroid cancer (2017) *Molecular and Cellular Endocrinology*, 443, pp. 121-127.
 15. Sabbadin, C., Mian, C., Nacamulli, D., Donà, G., Presotto, F., Betterle, C., Boscaro, M., Bordin, L., Armanini, D. Association of primary aldosteronism with chronic thyroiditis (2017) *Endocrine*, 55 (1), pp. 303-306.
 16. Cavedon, E., Barollo, S., Bertazza, L., Pennelli, G., Galuppini, F., Watutantrige-Fernando, S., Censi, S., Iacobone, M., Benna, C., Vianello, F., Zovato, S., Nacamulli, D., Mian, C. Prognostic Impact of miR-224 and RAS Mutations in Medullary Thyroid Carcinoma (2017). *Int J Endocrinol*. 2017;2017:4915736.
 17. Barollo S, Bertazza L, Watutantrige-Fernando S, Censi S, Cavedon E, Galuppini F, Pennelli G, Fassina A, Citton M, Rubin B, Pezzani R, Benna C, Opocher G, Iacobone M, Mian C. (2016) Overexpression of L-Type Amino Acid Transporter 1 (LAT1) and 2 (LAT2): Novel Markers of Neuroendocrine Tumors. (2016) *PLoS One*. Vol 25;11(5): e0156044.
 18. Pezzani R, Rubin B, Bertazza L, Redaelli M, Barollo S, Monticelli H, Baldini E, Mian C, Mucignat C, Scaroni C, Mantero F, Ulisse S, Iacobone M, Boscaro M. (2016) The aurora kinase inhibitor VX-680 shows anti-cancer effects in primary metastatic cells and the SW13 cell line. *Invest New Drugs*. Vol 34(5):531-40.

19. Censi S, Cavedon E, Fernando SW, Barollo S, Bertazza L, Zambonin L, Zaninotto M, Faggian D, Plebani M, Mian C. (2016) Calcitonin measurement and immunoassay interference: a case report and literature review. *Clin Chem Lab Med*. pii: /j/cclm.ahead-of-print/cclm-2015-1161/cclm-2015-1161.xml. doi: 10.1515/cclm-2015-1161. [Epub ahead of print] PubMed PMID: 27166721.
20. Galuppini F, Pennelli G, Vianello F, Censi S, Zambonin L, Watutantrige-Fernando S, Manso J, Nacamulli D, Lora O, Pelizzo MR, Rugge M, Barollo S, Mian C. (2016) BRAF analysis before surgery for papillary thyroid carcinoma: correlation with clinicopathological features and prognosis in a single-institution prospective experience. *Clin Chem Lab Med*. Vol 54(9):1531-9.
21. Sabbadin C, Mian C, Nacamulli D, Donà G, Presotto F, Betterle C, Boscaro M, Bordin L, Armanini D. (2016) Association of primary aldosteronism with chronic thyroiditis. *Endocrine*. Feb 9. [Epub ahead of print] PubMed PMID: 26860513.
22. Shi X, Liu R, Basolo F, Giannini R, Shen X, Teng D, Guan H, Shan Z, Teng W, Musholt TJ, Al-Kuraya K, Fugazzola L, Colombo C, Kebebew E, Jarzab B, Czarniecka A, Bendlova B, Sykorova V, Sobrinho-Simões M, Soares P, Shong YK, Kim TY, Cheng S, Asa SL, Viola D, Elisei R, Yip L, Mian C, Vianello F, Wang Y, Zhao S, Oler G, Cerutti JM, Puxeddu E, Qu S, Wei Q, Xu H, O'Neill CJ, Sywak MS, Clifton-Bligh R, Lam AK, Riesco-Eizaguirre G, Santisteban P, Yu H, Tallini G, Holt EH, Vasko V, Xing M. (2016) Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants. *J Clin Endocrinol Metab*. Vol 101(1):264-74.
23. Watutantrige Fernando S, Cavedon E, Nacamulli D, Pozza D, Ermolao A, Zaccaria M, Girelli ME, Bertazza L, Barollo S, Mian C. (2016) Iodine status from childhood to adulthood in females living in North-East Italy: Iodine deficiency is still an issue. *Eur J Nutr*. Vol 55(1):335-40.
24. Baldini E, Tuccilli C, Prinzi N, Sorrenti S, Antonelli A, Fallahi P, Mian C, Barollo S, Catania A, Morrone S, Tartaglia F, Mascagni D, Coccaro C, Pepe M, Filippini A, D'Armiento M, Ulisse S. (2015) Selective inhibitors of aurora kinases inhibit proliferation, reduce cell viability and impair cell cycle progression in papillary thyroid carcinoma cells. *J Biol Regul Homeost Agents*. Vol 29(4):793-803.
25. Rubin B, Monticelli H, Redaelli M, Mucignat C, Barollo S, Bertazza L, Mian C, Betterle C, Iacobone M, Fassina A, Boscaro M, Pezzani R, Mantero F. (2015) Mitogen-Activated Protein Kinase Pathway: Genetic Analysis of 95 Adrenocortical Tumors. *Cancer Invest*. Vol 33(10):526-31.
26. Tuccilli C, Baldini E, Sorrenti S, Di Gioia C, Bosco D, Ascoli V, Mian C, Barollo S, Rendina R, Coccaro C, Pepe M, Catania A, Bononi M, Tartaglia F, De Antoni E, D'Armiento M, Ulisse S. (2015) PAPILLARY THYROID CANCER IS CHARACTERIZED BY ALTERED EXPRESSION OF GENES INVOLVED IN THE SUMOYLATION PROCESS. *J Biol Regul Homeost Agents*. Vol 29(3):655-62.
27. Occhi G, Barollo S, Regazzo D, Bertazza L, Galuppini F, Guzzardo V, Jaffrain-Rea ML, Vianello F, Ciato D, Ceccato F, Watutantrige-Fernando S, Bisognin A, Bortoluzzi S, Pennelli G, Boscaro M, Scaroni C, Mian C. (2015) A constitutive active MAPK/ERK pathway due to BRAFV600E positively regulates AHR pathway in PTC. *Oncotarget*. Vol 13;6(31):32104-14.

28. Bertazza L, Barollo S, Radu CM, Cavedon E, Simioni P, Faggian D, Plebani M, Pelizzo MR, Rubin B, Boscaro M, Pezzani R, Mian C. (2015) Synergistic antitumour activity of RAF265 and ZSTK474 on human TT medullary thyroid cancer cells. *J Cell Mol Med.* Vol 19(9):2244-52.
29. Baldini E, Tuccilli C, Prinzi N, Sorrenti S, Falvo L, De Vito C, Catania A, Tartaglia F, Mocini R, Cocco C, Alessandrini S, Barollo S, Mian C, Antonelli A, De Antoni E, D'Armiento M, Ulisse S. (2015) Deregulated expression of Aurora kinases is not a prognostic biomarker in papillary thyroid cancer patients. *PLoS One.* Vol 25;10(3):e0121514.
30. Sabbadin C, Donà G, Bordin L, Iacobone M, Camozzi V, Mian C, Armanini D. (2015) Transient hypercortisolism and symptomatic hyperthyroidism associated to primary hyperparathyroidism in an elderly patient: case report and literature review. *BMC Endocr Disord.* Vol 28;15:4.
31. Xing M, Alzahrani AS, Carson KA, Shong YK, Kim TY, Viola D, Elisei R, Bendlová B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, Fagin JA, Puxeddu E, Fugazzola L, Czarniecka A, Jarzab B, O'Neill CJ, Sywak MS, Lam AK, Riesco-Eizaguirre G, Santisteban P, Nakayama H, Clifton-Bligh R, Tallini G, Holt EH, Sýkorová V. (2015) Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. *J Clin Oncol.* Vol 1;33(1):42-50.
32. Pennelli G, Galuppini F, Barollo S, Cavedon E, Bertazza L, Fassan M, Guzzardo V, Pelizzo MR, Rugge M, Mian C. (2015) The PDCD4/miR-21 pathway in medullary thyroid carcinoma. *Hum Pathol.* Vol 46(1):50-7.
33. Pelizzo MR, Torresan F, Boschini IM, Nacamulli D, Pennelli G, Barollo S, Rubello D, Mian C. (2015) Early, Prophylactic Thyroidectomy in Hereditary Medullary Thyroid Carcinoma: A 26-year Monoinstitutional Experience. *Am J Clin Oncol.* Vol 38(5):508-13.
34. Nacamulli, D., Petricca, D., Mian, C., Betterle, C. Selenium in Autoimmune Thyroiditis (2015) *Food and Nutritional Components in Focus*, 2015-January (9), pp. 458-478. DOI: 10.1039/9781782622215-00458; DOCUMENT TYPE: Book Chapter.
35. Mian C, Ceccato F, Barollo S, Watutantrige-Fernando S, Albiger N, Regazzo D, de Lazzari P, Pennelli G, Rotondi S, Nacamulli D, Pelizzo MR, Jaffrain-Rea ML, Grimaldi F, Occhi G, Scaroni C. (2014) AHR over-expression in papillary thyroid carcinoma: clinical and molecular assessments in a series of Italian acromegalic patients with a long-term follow-up. *PLoS One.* Vol 14; 9(7):e101560.
36. Simbolo M, Mian C, Barollo S, Fassan M, Mafficini A, Neves D, Scardoni M, Pennelli G, Rugge M, Pelizzo MR, Cavedon E, Fugazzola L, Scarpa A. (2014) High-throughput mutation profiling improves diagnostic stratification of sporadic medullary thyroid carcinomas. *Virchows Arch.* Vol 465(1):73-8.
37. Barollo S, Bertazza L, Baldini E, Ulisse S, Cavedon E, Boscaro M, Pezzani R, Mian C. (2014) The combination of RAF265, SB590885, ZSTK474 on thyroid cancer cell lines deeply impact on proliferation and MAPK and PI3K/Akt signaling pathways. *Invest New Drugs.* Vol 32(4):626-35.
38. Castinetti F, Qi XP, Walz MK, Maia AL, Sansó G, Peczkowska M, Hasse-Lazar K, Links TP, Dvorakova S, Toledo RA, Mian C, Bugalho MJ, Wohllk N, Kollyukh O, Canu L, Loli P, Bergmann SR, Biarnes Costa J, Makay O, Patocs A, Pfeifer M, Shah NS, Cuny T, Brauckhoff M, Bausch

- B, von Dobschuetz E, Letizia C, Barczynski M, Alevizaki MK, Czetwertynska M, Ugurlu MU, Valk G, Plukker JT, Sartorato P, Siqueira DR, Barontini M, Szperl M, Jarzab B, Verbeek HH, Zelinka T, Vlcek P, Toledo SP, Coutinho FL, Mannelli M, Recasens M, Demarquet L, Petramala L, Yaremchuk S, Zabolotnyi D, Schiavi F, Opocher G, Racz K, Januszewicz A, Weryha G, Henry JF, Brue T, Conte-Devolx B, Eng C, Neumann HP. (2014) Outcomes of adrenal-sparing surgery or total adrenalectomy in pheochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study. *Lancet Oncol* Vol 15(6):648-55.
39. Pelizzo MR, Dobrinja C, Casal Ide E, Zane M, Lora O, Toniato A, Mian C, Barollo S, Izuzquiza M, Guerrini J, De Manzini N, Merante Boschin I, Rubello D. (2014) The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma. *Biomed Pharmacother*. Vol 68(4):413-7.
40. Mian C, Perrino M, Colombo C, Cavedon E, Pennelli G, Ferrero S, De Leo S, Sarais C, Cacciatore C, Manfredi GI, Verga U, Iacobone M, De Pasquale L, Pelizzo MR, Vicentini L, Persani L, Fugazzola L. (2014) Refining calcium test for the diagnosis of medullary thyroid cancer: cutoffs, procedures, and safety. *J Clin Endocrinol Metab*. Vol 99(5):1656-64.
41. Russo E, Salzano M, De Falco V, Mian C, Barollo S, Secondo A, Bifulco M, Vitale M. (2014) Calcium/Calmodulin-dependent protein kinase II and its endogenous inhibitor α in medullary thyroid cancer. *Clin Cancer Res*. 2014 Vol 15; 20(6):1513-20.
42. Barollo S, Pezzani R, Cristiani A, Redaelli M, Zambonin L, Rubin B, Bertazza L, Zane M, Mucignat-Caretta C, Bulfone A, Pennelli G, Casal Ide E, Pelizzo MR, Mantero F, Moro S, Mian C. (2014) Prevalence, tumorigenic role, and biochemical implications of rare BRAF alterations. *Thyroid*. Vol 24(5):809-19.
43. Pezzani R, Rubin B, Redaelli M, Radu C, Barollo S, Cicala MV, Salvà M, Mian C, Mucignat-Caretta C, Simioni P, Iacobone M, Mantero F. (2014) The antiproliferative effects of ouabain and everolimus on adrenocortical tumor cells. *Endocr J*. Vol 61(1):41-53.
44. Nacamulli D, Petricca D, Mian C. Selenium and autoimmune thyroiditis. (2013) *J Endocrinol Invest*. Vol 36(10 Suppl): 8-14.
45. Ciampi R, Mian C, Fugazzola L, Cosci B, Romei C, Barollo S, Cirello V, Bottici V, Marconcini G, Rosa PM, Borrello MG, Basolo F, Ugolini C, Materazzi G, Pinchera A, Elisei R (2013). Evidence of a Low Prevalence of RAS Mutations in a Large Medullary Thyroid Cancer Series. *THYROID*. Vol. 23(1):50-7.
46. Pennelli G, Fassan M, Mian C, Pizzi M, Balistreri M, Barollo S, Galuppini F, Guzzardo V, Pelizzo M, Ruge M (2013). PDCD4 expression in thyroid neoplasia. *VIRCHOWS ARCHIV*. Vol. 462(1):95-100.
47. Papale F, Cafiero G, Grimaldi A, Marino G, Rosso F, Mian C, Barollo S, Pennelli G, Sorrenti S, De Antoni E, Barbarisi A. (2013) Galectin-3 expression in thyroid fine needle cytology (t-FNAC) uncertain cases: validation of molecular markers and technology innovation. *J Cell Physiol*. Vol 228(5):968-74.

48. Watutantrige Fernando S, Barollo S, Nacamulli D, Pozza D, Giachetti M, Frigato F, Redaelli M, Zagotto G, Girelli ME, Mantero F, Mian C (2013). Iodine status in schoolchildren living in northeast Italy: the importance of iodized-salt use and milk consumption. *Eur J Clin Nutr.* Vol 67(4):366-70.
49. Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, Fagin JA, Puxeddu E, Fugazzola L, Czarniecka A, Jarzab B, O'Neill CJ, Sywak MS, Lam AK, Riesco-Eizaguirre G, Santisteban P, Nakayama H, Tufano RP, Pai SI, Zeiger MA, Westra WH, Clark DP, Clifton-Bligh R, Sidransky D, Ladenson PW, Sykorova V (2013). Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. *JAMA.* Vol 309(14):1493-501.
50. Barollo S, Pezzani R, Cristiani A, Bertazza L, Rubin B, Bulfone A, Pelizzo MR, Torresan F, Mantero F, Pennelli G, Moro S, Mian C (2013). Functional Significance of the Novel H-RAS Gene Mutation M72I in a Patient with Medullary Thyroid Cancer.. *EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES* Vol 121(9):546-550.
51. C. Mian, P. Sartorato, S. Barollo, M. Zane, G. Opocher (2012). RET codon 609 mutations: a contribution for better clinical managing. *CLINICS.* Vol. 67, p. 33-36.
52. C. Colombo, U. Verga, C. Mian, S. Ferrero, M. Perrino, L. Vicentini, D. Dazzi, G. Opocher, M. R. Pelizzo, P. Beck-Peccoz, L. Fugazzola (2012). Comparison of Calcium and Pentagastrin Tests for the Diagnosis and Follow-Up of Medullary Thyroid Cancer. *J Clin Endocrinol Metab.* Vol. 97, p. 905-913.
53. Mian C, Pennelli G, Fassan M, Balistreri M, Barollo S, Cavedon E, Galuppini F, Pizzi M, Vianello F, Pelizzo MR, Girelli M, Rugge M, Opocher G (2012). microRNA profiles in familial and sporadic medullary thyroid carcinoma: preliminary relationships with RET status and outcome.. *THYROID.* Vol 22(9):890-6.
54. Ulisse S, Baldini E, Sorrenti S, Barollo S, Prinzi N, Catania A, Nesca A, Gnessi L, Pelizzo MR, Mian C, De Vito C, Calvanese A, Palermo S, Persechino S, De Antoni E, D'Armiento M (2012). In papillary thyroid carcinoma BRAF(V600E) is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval. *CLINICAL ENDOCRINOLOGY.* Vol 77(5):780-6.
55. Nacamulli D, Nico L, Barollo S, Zambonin L, Pennelli G, Girelli ME, Ide EC, Rosa PM, Vianello F, Negro I, Watutantrige-Fernando S, Mantero F, Rugge M, Mian C (2012). Comparison Of The Diagnostic Accuracy Of Combined Elastasonography And Braf Analysis Versus Cytology And Ultrasonography For Thyroid Nodule Suspected Of Malignancy. *CLINICAL ENDOCRINOLOGY,* Vol 77(4):608-14.
56. Petricca D, Nacamulli D, Mian C, Mantero F, Cavedon E, Girelli ME, Betterle C (2012). Effects of selenium supplementation on the natural course of autoimmune thyroiditis: A short review. *JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION* Vol. 35, 35(4):419-24.
57. Vianello F, Mazzarotto R, Mian C, Lora O, Saladini G, Servodio O, Basso M, Pennelli G, Pelizzo MR, Sotti G (2012). Clinical outcome of low-risk differentiated thyroid cancer patients after

radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation. *CLINICAL ONCOLOGY*. Vol. 24, p. 162-168.

58. Mian C., Nacamulli D., Nico L. (2012). Thyroid node assessment: how can we avoid unnecessary surgical procedures? *EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM* Vol. 7, p. 583-585.
59. Calebiro D, Gelmini G, Cordella D, Bonomi M, Winkler F, Biebermann H, de Marco A, Marelli F, Libri DV, Antonica F, Vigone MC, Cappa M, Mian C, Sartorio A, Beck-Peccoz P, Radetti G, Weber G, Persani L. (2012). Frequent TSH Receptor Genetic Alterations with Variable Signaling Impairment in a Large Series of Children with Nonautoimmune Isolated Hyperthyrotropinemia. *J Clin Endocrinol Metab*. Vol. 97(1):E156-60.
60. ULISSE S, BALDINI E, SORRENTI S, BAROLLO S, GNESSI L, CATANIA A, PELLIZZO MR, NARDI F, C. MIAN, DE ANTONI E, D'ARMIENTO M, FRATI L (2011). High Expression of the Urokinase Plasminogen Activator and Its Cognate Receptor Associates with Advanced Stages and Reduced Disease-Free Interval in Papillary Thyroid Carcinoma. *J Clin Endocrinol Metab*. Vol. 96(2), p. 504-508.
61. FRANK-RAUE K, RYBICKI LA, ERLIC Z, SCHWEIZER H, WINTER A, MILOS I, TOLEDO SP, TOLEDO RA, TAVARES MR, ALEVIZAKI M, C. MIAN, SIGGELKOW H, HÜFNER M, WOHLK N, OPOCHER G, DVO, ÁKOVÁ S, BENDLOVA B, CZETWERTYNSKA M, SKASKO E, BARONTINI M, SANSOG, VORLÄNDER C, MAIA AL, PATOCS A, LINKS TP, DE GROOT JW, KERSTENS MN, VALK GD, MIEHLE K, MUSHOLT TJ, BIARNES J, DAMJANOVIC S, MURESAN M, WÜSTER C, FASSNACHT M, PECZKOWSKA M, FAUTH C, GOLCHER H, WALTER MA, PICHL J, RAUE F, ENG C, NEUMANN HP, FOR THE INTERNATIONAL RET EXON CONSORTIUM (2011). Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10. *HUMAN MUTATION* Vol. 32, p. 51-58.
62. MIAN C, PENNELLI G, BAROLLO S, CAVEDON E, NACAMULLI D, VIANELLO F, NEGRO I, POZZA G, BOSCHIN IM, PELIZZO MR, M. RUGGE, MANTERO F, GIRELLI ME, OPOCHER G (2011). Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification. *EUROPEAN JOURNAL OF ENDOCRINOLOGY*. Vol. 164, p. 971-976.
63. Baldini E, Arlot-Bonnemains Y, Sorrenti S, C. MIAN, Pelizzo MR, De Antoni E, Palermo S, Morrone S, Barollo S, Nesca A, Moretti CG, D'Armiento M, Ulisse S (2011). Aurora kinases are expressed in medullary thyroid carcinoma (MTC) and their inhibition suppresses in vitro growth and tumorigenicity of the MTC derived cell line TT. *BMC CANCER*. Vol. 26;11:411.
64. Pennelli G, Vianello F, Barollo S, Pezzani R, Merante Boschini I, Pelizzo MR, Mantero F, Rugge M, Mian C (2011). BRAF(K601E) mutation in a patient with a follicular thyroid carcinoma. *THYROID*. Vol. 21, p. 1393-1396.
65. Pelizzo MR, Boschini IM, Barollo S, Pennelli G, Toniato A, Zambonin L, Vianello F, Piotta A, Ide EC, Pagetta C, Sorgato N, Torresan F, Girelli ME, Nacamulli D, Mantero F, Mian C (2011). BRAF analysis by fine needle aspiration biopsy of thyroid nodules improves preoperative identification

of papillary thyroid carcinoma and represents a prognostic factor. A mono-institutional experience. *CLINICAL CHEMISTRY AND LABORATORY MEDICINE*. Vol. 49, p. 325-329.

66. Vianello F, Mazzarotto R, Taccaliti A, Lora O, Basso M, Servodio O, Mian C, Sotti G. (2011) Follicular thyroid carcinoma with metastases to the pituitary causing pituitary insufficiency. *Thyroid*. Vol 21(8):921-5.
67. ROMEI C, MARIOTTI S, FUGAZZOLA L, TACCALITI A, PACINI F, OPOCHER G., MIAN C, CASTELLANO M, DEGLI UBERTI E, CECCHERINI I, CREMONINI N, SEREGNI E, ORLANDI F, FEROLLA P, PUXEDDU E, GIORGINO F, COLAO A, LOLI P, BONDI F, COSCI B, BOTTICI V, CAPPALÀ A, PINNA G, PERSANI L, VERGA U, BOSCARO M, CASTAGNA MG, CAPPELLI C, ZATELLI MC, FAGGIANO A, FRANCIA G, BRANDI ML, FALCHETTI A, PINCHERA A, ELISEI R (2010). Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. *EUROPEAN JOURNAL OF ENDOCRINOLOGY*. Vol. 163, p. 301-308.
68. NACAMULLI D, MIAN C, PETRICCA D, LAZZAROTTO F, BAROLLO S, POZZA D, MASIERO S, FAGGIAN D, PLEBANI M, GIRELLI M.E., MANTERO F, BETTERLE C (2010). INFLUENCE OF PHYSIOLOGICAL DIETARY SELENIUM SUPPLEMENTATION ON THE NATURAL COURSE OF AUTOIMMUNE THYROIDITIS . *CLINICAL ENDOCRINOLOGY*. Vol. 73(4), p. 535-539.
69. BAROLLO S, PENNELLI G, VIANELLO F, WATUTANTRIGE FERNANDO S, NEGRO I, MERANTE, BOSCHIN I, PELIZZO MR, RUGGE M, MANTERO F, NACAMULLI D, GIRELLI M.E., BUSNARDO B, MIAN C (2010). BRAF in primary and recurrent papillary thyroid cancers the relationship with (131) I and 2 [(18)F] fluoro-2-deoxy-D-glucose uptake ability.. *EUROPEAN JOURNAL OF ENDOCRINOLOGY*. Vol. 163(4), p. 659-663.
70. Sanguin F, Albiger N, Betterle C, Mian C, Gatti R, Rossi E, Mantero F, Scaroni C. (2010) Diagnostic and therapeutic challenge in the management of a patient with ectopic adrenocorticotropin secretion. *J Endocrinol Invest*. Vol 33(7):507-8.
71. PENNELLI G, MIAN C, PELIZZO MR, NACCAMULLI D, PIOTTO A, GIRELLI ME, MESCOLI C, RUGGE M (2009). Galectin-3 cytostest in thyroid follicular neoplasia: a prospective, monoinstitutional study. *ACTA CYTOLOGICA*. Vol. 9, p. 533-539.
72. MIAN C, VITALIANO P, POZZA D, BAROLLO S, PITTON M, CALLEGARI G, GIANANTONIO, ED, CASARO A, NACAMULLI D, BUSNARDO B, MANTERO F, M. GIRELLI (2009). Iodine status in pregnancy: role of dietary habits and geographical origin. *CLINICAL ENDOCRINOLOGY*. Vol. 70(5), p. 776-780.
73. C. Mian, S. Barollo, L. Zambonin, G. Pennelli, P. Bernante, M. R. Pelizzo, D. Nacamulli, F. Mantero, M. E. Girelli, G. Opocher (2009). Characterization of the largest kindred with MEN2A due to a Cys609Ser RET mutation. *FAMILIAL CANCER*, Vol. 8, p. 379-382.
74. MIAN C, BAROLLO S, PENNELLI G., PAVAN N, RUGGE M, PELIZZO MR, MAZZAROTTO R, CASARA D, NACAMULLI D, MANTERO F, OPOCHER G, BUSNARDO B, GIRELLI ME (2008). Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake. *CLINICAL ENDOCRINOLOGY* Vol. 68, p. 108-116.

75. BARTOLAZZI A, ORLANDI F, SAGGIORATO E, VOLANTE M, ARECCO F, ROSSETTO R, PALESTINI N, GHIGO E, PAPOTTI M, BUSSOLATI G, MARTEGANI MP, PANTELLINI F, CARPI A, GIOVAGNOLI MR, MONTI S, TOSCANA V, SCIACCHITANO S, PENNELLI GM, MIAN C, PELIZZO MR, RUGGE M, TRONCONE G, PALOMBINI L, CHIAPPETTA G, BOTTI G, VECCHIONE A, BELLOCCO R (2008). Galectin-3-expression analyses in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. *LANCET ONCOLOGY* Vol. 9, p. 543-549.
76. FUGAZZOLA L, MUZZA M, MIAN C, CORDELLA D, BAROLLO S, ALBERTI L, CIRELLO V, DAZZI D, GIRELLI M.E., OPOCHER G, BECK-PECCOZ P, PERSANI L (2008). RET genotypes in sporadic medullary thyroid cancer: studies in a large Italian series. *CLINICAL ENDOCRINOLOGY* Vol. 69, p. 418-425.
77. PELIZZO MR, MERANTE BOSCHIN I, TONIATO A, PAGETTA C, CASAL IDE E, MIAN C., RUBELLO D (2008). Diagnosis treatment, prognostic factors and long-term outcome in papillary thyroid carcinoma. *MINERVA ENDOCRINOLOGICA* Vol. 33(4), p. 359-379.
78. MIAN C, OPOCHER G. (2007) Hereditary medullary thyroid carcinoma (MTC): the molecular screening. *Thyroidology Clinical and Experimental* Vol 19-20, p.4-7. ISSN: 11217596
79. LACROIX L, MICHIELS S, C. MIAN, ARTURI F, CAILLOU B, FILETTI S, SCHLUMBERGER M, BIDART JM (2006). HEX, PAX-8 and TTF-1 gene expression in human thyroid tissues: a comparative analysis with other genes involved in iodide metabolism. *CLINICAL ENDOCRINOLOGY* Vol. 64, p. 398-404.
80. OPOCHER G, SCHIAVI F, IACOBONE M, TONIATO A, SATTAROVA S, ERLIC Z, MARTELLA M, MIAN C, MERANTE BOSCHIN I, ZAMBONIN L, DE LAZZARI P, MURGIA A., PELIZZO MR, FAVIA G, MANTERO F (2006). Familial nonsyndromic pheochromocytoma. *ANNALS OF THE NEW YORK ACADEMY OF SCIENCES* Vol. 1073, p. 149-155.
81. BUSNARDO B, NACAMULLI D, ZAMBONIN L, C. MIAN, PICCOLO M, GIRELLI ME (2006). Restricted intraindividual urinary iodine concentration variability in nonfasting subjects. *EUROPEAN JOURNAL OF CLINICAL NUTRITION*. Vol. 60, p. 421-425.
82. LACROIX L, C. MIAN, BARRIER T, TALBOT M, CAILLOU B, SCHLUMBERGER M, BIDART JM (2004). PAX8 and peroxisome proliferator-activated receptor gamma 1 gene expression status in benign and malignant thyroid tissues. *EUROPEAN JOURNAL OF ENDOCRINOLOGY*. Vol. 151, p. 367-374.
83. GIRELLI ME, COIN P, MIAN C, NACAMULLI D, ZAMBONIN L, PICCOLO M, VIANELLO-DRI A, GOTTARDO F., BUSNARDO B (2004). Milk represents an important source of iodine in schoolchildren of the Veneto region, Italy. *JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION*. Vol. 27, p. 709-713.
84. BUSNARDO B, NACAMULLI D, FRIGATO F, VIANELLO DRI A, DE VIDO D, MIAN C, CANDIANI F, TOMASELLA G, ZAMBONIN L, PICCOLO M, M. GIRELLI (2003). Normal values for thyroid ultrasonography, goiter prevalence and urinary iodine concentration in schoolchildren

of the Veneto Region, Italy. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION. Vol. 26, p. 991-996.

85. LACROIX L, NOCERA M, C. MIAN, CAILLOU B, VIRION A, DUPUY C, FILETTI S, BIDART JM, SCHLUMBERGER M (2001). Expression of nicotinamide adenine dinucleotide phosphate oxidase flavoprotein DUOX genes and proteins in human papillary and follicular thyroid carcinomas. THYROID. Vol. 11, p. 1017-1023.
86. C. MIAN, LACROIX L, ALZIEU L, NOCERA M, TALBOT M, BIDART JM, SCHLUMBERGER M, CAILLOU B (2001). Sodium iodide symporter and pendrin expression in human thyroid tissues. THYROID Vol. 11, p. 825-830.
87. LACROIX L, C. MIAN, CAILLOU B, TALBOT M, FILETTI S, SCHLUMBERGER M, BIDART JM (2001). Na⁺/I⁻ symporter and Pendred syndrome gene and protein expressions in human extra-thyroidal tissues. EUROPEAN JOURNAL OF ENDOCRINOLOGY. Vol. 144, p. 297-302.
88. C. MIAN, LACROIX L, BIDART JM, CAILLOU B, FILETTI S, SCHLUMBERGER M (2001). Sodium/iodide symporter in thyroid cancer. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES. Vol. 109, p. 47-51.
89. BIDART JM, C. MIAN, LAZAR V, RUSSO D, FILETTI S, CAILLOU B, SCHLUMBERGER M (2000). Expression of pendrin and the Pendred Syndrome (PDS) gene in human thyroid tissues. THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM. Vol. 85, p. 2028-2033.
90. B.BUSNARDO, O.DANIELE, M.R.PELIZZO, R.MAZZAROTTO, D.NACAMULLI, D.DEVIDO, C.MIAN, GIRELLI M.E. (2000). A Multimodality therapeutic approach in anaplastic thyroid carcinoma: study on 39 patients. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION. Vol. 23, p. 755-761.
91. BUSNARDO B, GIRELLI ME, FRIGATO F, VIANELLO DRI A, NACAMULLI D, CERISARA D, DE VIDO D, MIAN C, GAROLA E (1998). GOZZO E CARENZA IODICA NEL VENETO: STUDIO SU 6285 RAGAZZI DELLE SCUOLE ELEMENTARI E MEDIE. Vol. 3, p. 437-441.
92. GIRELLI ME, NACAMULLI D, PELIZZO MR, DE VIDO D, C. MIAN, PICCOLO M, BUSNARDO B (1998). Medullary thyroid carcinoma: Clinical features and long-term follow-up of seventy-eight patients treated between 1969 and 1986. THYROID. Vol. 8, p. 517-523.